role of faecal microbialtransplantation in patients of Irritable Bowel Syndrome
Not Applicable
- Conditions
- Health Condition 1: K588- Other irritable bowel syndrome
- Registration Number
- CTRI/2020/02/023269
- Lead Sponsor
- Artemis Health Institute
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
All patients of IBS fulfilling the ROME IV Criteria
1.Compliance to undergo colonoscopy and FMT procedure
2.Irritable Bowel Syndrome Severity Scoring Symptom (IBS-SSS) > 175
Exclusion Criteria
1. Antibiotic therapy in past 3 months
2.Inflammatory bowel disease (IBD)
3.Patients who will decline informed consent or are unwilling to participate in study
4.Pregnancy
5.Alternative diagnosis to IBS such as infective diarrhoea, microscopic colitis
6.Food allergy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Improvement in IBS symptoms by Irritable Bowel Syndrome Severity Scoring Symptom (IBSSSS)50 points after faecal microbial transplantationTimepoint: 3 months
- Secondary Outcome Measures
Name Time Method Improvement in IBS symptoms by Irritable Bowel Syndrome Severity Scoring Symptom (IBSSSS)after faecal microbial transplantation after 6 monthsTimepoint: 6 months